Cell & Gene Therapies

(Image: Getty/pinkypills)

Nightstar acquired by Biogen for $800m

By Maggie Lynch

Biogen agrees Nightstar acquisition for $800m to take on its pipeline of AAV treatments for retinal disorders, diversifyingy its pipeline in the rare disease market.

(Image: Getty/Dr_Microbe)

Cell therapy market to triple in size by 2025

By Ben Hargreaves

The market for cell therapy products is set to expand based on increasing investment from the industry and the implementation of advanced manufacturing technologies.

(Image: Getty/Phototechno)

How to solve a problem like Kymriah

By Ben Hargreaves

In its full-year financials, Novartis announced plans to transform its cell therapy manufacturing process through greater investment and utilisation of digital technologies.

(Image: Getty/wildpixel)

CAR-T for solid tumors drives industry to innovate

By Maggie Lynch

ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.

(Image: Getty/exdez)

bioProcessUK Conference

Outgoing GSK exec shares four industry mega-trends

By Flora Southey

A number of global ‘mega-trends’, such as dated technology and manufacturing inefficiencies, present major challenges for the drug industry, according to Dave Tudor

Follow us

Webinars